Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 6/2010

01-04-2010 | Review Article

Rabbit Antithymocyte Globulin (Thymoglobulin®)

25 Years and New Frontiers in Solid Organ Transplantation and Haematology

Authors: Dr A. Osama Gaber, Anthony P. Monaco, James A. Russell, Yvon Lebranchu, Mohamad Mohty

Published in: Drugs | Issue 6/2010

Login to get access

Abstract

The more than 25 years of clinical experience with rabbit antithymocyte globulin (rATG), specifically Thymoglobulin®, has transformed immuno-suppression in solid organ transplantation and haematology. The utility of rATG has evolved from the treatment of allograft rejection and graft-versus-host disease to the prevention of various complications that limit the success of solid organ and stem cell transplantation. Today, rATG is being successfully incorporated into novel therapeutic regimens that seek to reduce overall toxicity and improve long-term outcomes. Clinical trials have demonstrated the efficacy and safety of rATG in recipients of various types of solid organ allografts, recipients of allogeneic stem cell transplants who are conditioned with both conventional and nonconventional regimens, and patients with aplastic anaemia. Over time, clinicians have learnt how to better balance the benefits and risks associated with rATG. Advances in the understanding of the multifaceted mechanism of action will guide research into new therapeutic areas and future applications.
Literature
1.
Metchnikoff E. Studies on the resorption of cells. Ans Inst Pasteur 1899; 13: 737–7
2.
Woodruff MF, Anderson NA. Effect of lymphocyte depletion by thoracic duct fistula and administration of antilymphocytic serum on the survival of skin homografts in rats. Nature 1963 Nov 16; 200: 702PubMedCrossRef
3.
Monaco AP, Wood ML, Gray JG, et al. Studies on heterologous anti-lymphocyte serum in mice, II: effect on the immune response. J Immunol 1966 Feb; 96(2): 229–38PubMed
4.
Monaco AP, Abbott WM, Othersen HB, et al. Antiserum to lymphocytes: prolonged survival of canine renal allografts. Science 1966 Sep 9; 153(741): 1264–7PubMedCrossRef
5.
Monaco AP, Codish SD. Survey of the current status of the clinical uses of antilymphocyte serum. Surg Gynecol Obstet 1976 Mar; 142(3): 417–26PubMed
6.
Monaco AP, Wood ML, Russell PS. Some effects of purified heterologous antihuman lymphocyte serum in man. Transplantation 1967 Jul; 5 Suppl. 4: 1106–14PubMedCrossRef
7.
Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963 Jun 13; 268: 1315–23PubMedCrossRef
8.
Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967 Feb; 124(2): 301–8PubMed
9.
Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. BMJ 1970 Apr 18; 2(5702): 131–6PubMedCrossRef
10.
Shield III CF, Cosimi AB, Tolkoff-Rubin N, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979 Dec; 28(6): 461–4PubMed
11.
Birkeland SA. A controlled clinical trial of treatment with ALG in established rejection of renal allografts. Acta Med Scand 1975 Dec; 198(6): 489–96PubMedCrossRef
12.
Hardy MA, Nowygrod R, Elberg A, et al. Use of ATG in treatment of steroid-resistant rejection. Transplantation 1980 Feb; 29(2): 162–4PubMedCrossRef
13.
Sheil AG, Kelly GE, Storey BG, et al. Controlled clinical trial of antilymphocyte globulin in patients with renal allografts from cadaver donors. Lancet 1971 Feb 20; 1(7695): 359–63PubMedCrossRef
14.
Thomas F, Mendez-Picon G, Thomas J, et al. Effect of antilymphocyte-globulin potency on survival of cadaver renal transplants: prospective randomised double-blind trial. Lancet 1977 Oct 1; 2(8040): 671–4PubMedCrossRef
15.
Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by anti-thymocyte globulin. Blood 1974 Jul; 44(1): 56–75PubMed
16.
Doney KC, Weiden PL, Storb R, et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11(1): 1–8PubMedCrossRef
17.
Ramsay NK, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982 Feb 18; 306(7): 392–7PubMedCrossRef
18.
Weiden PL, Doney K, Storb R, et al. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease: a randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979 Apr; 27(4): 227–30PubMedCrossRef
19.
Speck B, Gluckman E, Haak HL, et al. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 1977 Dec 3; 2(8049): 1145–8PubMedCrossRef
20.
Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) 1981 Mar 14; 282(6267): 860–3CrossRef
21.
Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia, XI: results of immunosuppressive treatment of 37 patients. Blood 1984 Feb; 63(2): 277–86PubMed
22.
Marmont A, Peschle C, Sanguineti M, et al. Pure red cell aplasia (PRCA): response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis. Blood 1975 Feb; 45(2): 247–61PubMed
23.
Matas AJ, Sutherland DE, Najarian JS. Evolution of immunosuppression at the University of Minnesota. Transplant Proc 2004 Mar; 36 Suppl. 2: 64S–70SPubMedCrossRef
24.
Najarian JS, Simmons RL, Condie RM, et al. Seven years’ experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976 Sep; 184(3): 352–68PubMedCrossRef
25.
Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999 Apr 15; 67(7): 1011–8PubMedCrossRef
26.
Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 Nov 9; 355(19): 1967–77PubMedCrossRef
27.
Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006 May; 12(5): 560–5PubMedCrossRef
28.
Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999 Nov; 107(2): 330–4PubMedCrossRef
29.
Thymoglobulin® (anti-thymocyte globulin [rabbit]) [package insert]. Cambridge (MA): Genzyme Corporation, 2008
30.
Pistillo MP, Tazzari PL, Bonifazi F, et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002 Apr 27; 73(8): 1295–302PubMedCrossRef
31.
Rebellato LM, Gross U, Verbanac KM, et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994 Mar 15; 57(5): 685–94PubMedCrossRef
32.
Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007 Jul; 21(7): 1387–94PubMedCrossRef
33.
Mueller TF. Mechanisms of action of Thymoglobulin. Transplantation 2007 Dec 15; 84(11S): S5–10CrossRef
34.
Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003 Mar 15; 75(5): 657–62PubMedCrossRef
35.
Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998 Jul 15; 66(1): 29–37PubMedCrossRef
36.
Mariat C, Alamartine E, Diab N, et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 1998; 11(3): 231–6PubMed
37.
O’Donoghue DJ, Johnson RW, Mallick NP, et al. Rabbit anti-thymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplant Proc 1989 Feb; 21 (1 Pt 2): 1736–7PubMed
38.
Bock P, Hobler N, Caudrelier P, et al. Treatment of acute rejection in renal graft recipients by thymoglobuline: a retrospective multicenter analysis. Transplant Proc 1995 Feb; 27(1): 1058–9PubMed
39.
Clark KR, Forsythe JL, Shenton BK, et al. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int 1993 Jan; 6(1): 18–21PubMedCrossRef
40.
Daoud AJ, Schroeder TJ, Kano J, et al. The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection. Transplant Proc 1997 Nov; 29(7A): 18S–20SPubMedCrossRef
41.
Zaltzman JS, Paul LC. Single center experience with thymoglobulin in renal transplantation. Transplant Proc 1997 Nov; 29(7A): 27S–8SPubMedCrossRef
42.
Rosenberg L. Pancreas transplantation with ATG vs OKT 3. Transplant Proc 1997 Nov; 29(7A): 35S–6SPubMed
43.
Cantarovich D, Karam G, Giral-Classe M, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998 Oct; 54(4): 1351–6PubMedCrossRef
44.
Tchervenkov J, Flemming C, Guttmann RD, et al. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transplant Proc 1997 Nov; 29(7A): 13S–5SPubMedCrossRef
45.
Carrier M, White M, Perrault LP, et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999 Dec; 18(12): 1218–23PubMedCrossRef
46.
Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000 May 15; 69(9): 1890–8PubMedCrossRef
47.
Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003 Apr; 125(4): 891–900PubMedCrossRef
48.
Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of Thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004 Jul 15; 78(1): 136–41PubMedCrossRef
49.
Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008 Oct 15; 86(7): 947–52PubMedCrossRef
50.
Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs alemtuzumab (with lower dose maintenance immunosuppression) vs daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008 Mar–Apr; 22(2): 200–10PubMedCrossRef
51.
Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunologicalrisk renal transplant recipients. J Am Soc Nephrol 2009 Jun; 20(6): 1385–92PubMedCrossRef
52.
Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003 Sep 15; 76(5): 798–802PubMedCrossRef
53.
Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008 May 27; 85(10): 1391–9PubMedCrossRef
54.
Schnetzler B, Leger P, Völp A, et al. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int 2002 Jun; 15(6): 317–25PubMedCrossRef
55.
Bonaros N, Dunkler D, Kocher A, et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant 2006 Sep; 25(9): 1154–63PubMedCrossRef
56.
Chappell D, Beiras-Fernandez A, Hammer C, et al. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006 Feb 27; 81(4): 552–8PubMedCrossRef
57.
Hammer C, Thein E. Visualization of the effect of polyclonal antithymocyte globulins on adhesion of leukocytes. Transplant Proc 2002 Sep; 34(6): 2486–7PubMedCrossRef
58.
Bogetti D, Sankary HN, Jarzembowski TM, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005 Aug; 19(4): 507–11PubMedCrossRef
59.
Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004 Aug 27; 78(4): 584–90PubMedCrossRef
60.
Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002 Jan; 2(1): 48–56PubMedCrossRef
61.
Heilman RL, Reddy KS, Mazur MJ, et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 2006 Jun; 38(5): 1307–13PubMedCrossRef
62.
Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009 May 27; 87(10): 1520–9PubMedCrossRef
63.
Peddi VR, Ueda K, Bry W, et al. Comparison of Simulect and Thymoglobulin induction in an early steroid cessation protocol in renal transplant recipients [abstract no. 1190]. American Transplant Congress; 2007 May 5–9; San Francisco (CA)
64.
Baron PW, Ojogho O, Sahney S, et al. Low dose antithymocyte globulin compared to basiliximab induction therapy in pediatric kidney transplantation [abstract no. 1335]. American Transplant Congress; 2005 May 21–25; Seattle (WA)
65.
Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004 Sep 27; 78(6): 904–10PubMedCrossRef
66.
Knight RJ, Schoenberg L, Kerman RH, et al. Four-year outcomes comparing Thymoglobulin and basiliximab in combination with sirolimus and reduced-dose cyclosporine for high versus low immune responders [abstract no. 1452]. American Transplant Congress; 2007 May 5–9; San Francisco (CA)
67.
Chuang P, Buchanan C, Kizikisik T, et al. A nonrandomized, retrospective review of Simulect versus Thymoglobulin as induction agents for kidney transplantation at a single transplant center [abstract no. 2309]. World Transplant Congress; 2006 Jul 22–27; Boston (MA)
68.
Mulgoankar S, Hanaway M, Woodle ES, et al. Continuing 24 month results of a multicenter randomized trial comparing three induction agents (alemtuzumab, Thymoglobulin, and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no. 312]. American Transplant Congress; 2009 May 30–Jun 3; Boston (MA)
69.
Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008 Oct 16; 359(16): 1736–8PubMedCrossRef
70.
71.
Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc 2005 Mar; 37(2): 889–91PubMedCrossRef
72.
Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009 May 15; 87(9): 1372–6PubMedCrossRef
73.
74.
Gaber AO, Matas AJ, Ferguson RM, et al. Thymoglobulin induction in living donor renal transplant recipients: update of the TAILOR registry [abstract no. 878]. XXII International Congress of The Transplantation Society; 2008 Aug 10–14; Sydney (NSW)
75.
Miller JT, Collins CD, Stuckey LJ, et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009 Oct; 29(10): 1166–74PubMedCrossRef
76.
Annual report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1997–2006. Rockville (MD): Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2007 [online]. Available from URL: http://​www.​optn.​org/​AR2007/​default.​htm [Accessed 2008 Jul 31]
77.
Veenstra DL, Best JH, Hornberger J, et al. Incidence and cost of steroid side effects after renal transplantation. Transplant Proc 1999 Feb–Mar; 31(1–2): 301–2PubMedCrossRef
78.
Sinclair NR. Low-dose steroid therapy in cyclosporinetreated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992 Sep 1; 147(5): 645–57PubMed
79.
Lebranchu Y, Aubert P, Bayle F, et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group. Transplant Proc 2000 Mar; 32(2): 396–7PubMedCrossRef
80.
Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001 Apr 27; 71(8): 1089–90PubMedCrossRef
81.
Khwaja K, Asolati M, Harmon JV, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004 Nov 15; 78(9): 1397–9PubMedCrossRef
82.
Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression: a 5-year experience. Am J Transplant 2005 Oct; 5(10): 2473–8PubMedCrossRef
83.
Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: an interim analysis. Am J Transplant 2005 Jun; 5(6): 1529–36PubMedCrossRef
84.
Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008 Oct; 248(4): 564–77PubMed
85.
Woodle ES, Peddi VR, Tomlanovich S, et al. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. Clin Transplant 2009 Nov 20; (24): 73–83
86.
Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002 Jan 27; 73(2): 169–77PubMedCrossRef
87.
Freise CE, Kang SM, Feng S, et al. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. Transplant Proc 2004 May; 36(4): 1067–8PubMedCrossRef
88.
Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation 2006 Aug 15; 82(3): 389–92PubMedCrossRef
89.
Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001 Aug; 7(8): 693–7PubMedCrossRef
90.
Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 Apr 27; 75(8): 1396–9PubMedCrossRef
91.
Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008 Jan–Feb; 22(1): 76–81PubMed
92.
Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001 Sep 27; 72(6): 1050–5PubMedCrossRef
93.
Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003 Mar 27; 75(6): 844–51PubMedCrossRef
94.
Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004 Apr 27; 77(8): 1228–35PubMedCrossRef
95.
Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 Mar; 6(3): 514–22PubMedCrossRef
96.
Büchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 Nov; 7(11): 2522–31PubMedCrossRef
97.
Eason JD, Saharia A, Vera S, et al. Rabbit ATG induction as a calcineurin inhibitor-sparing protocol in steroid-free liver transplantation [abstract no. 634]. American Transplant Congress; 2007 May 5–9; San Francisco (CA)
98.
Tchervenkov JI, Tzimas GN, Cantarovich M, et al. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004 Jul–Aug; 36(6): 1747–52PubMed
99.
Tector AJ, Fridell JA, Mangus RS, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004 Mar; 10(3): 404–7PubMedCrossRef
100.
Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007 Jul; 13(7): 1039–44PubMedCrossRef
101.
Bajjoka I, Hsaiky L, Brown K, et al. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008 Jan; 14(1): 66–72PubMedCrossRef
102.
Cantarovich M, Tchervenkov J, Barkun J, et al. Long-term renal function in liver transplant patients with postoperative renal dysfunction receiving anti-thymocyte globulin induction and delayed calcineurin inhibitors [abstract no. 1578]. Am J Transplant 2007; 7 Suppl. 2
103.
Cantarovich M, Giannetti N, Barkun J, et al. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004 Sep 15; 78(5): 779–81PubMedCrossRef
104.
Grinyó JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003 Nov; 16(11): 820–7PubMed
105.
Grinyó JM, Gil-Vernet S, Seron D, et al. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Nephrol Dial Transplant 1998 Oct; 13(10): 2601–4PubMedCrossRef
106.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 Sep 4; 349(10): 931–40PubMedCrossRef
107.
Delgado DH, Miriuka SG, Cusimano RJ, et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 2005 Feb; 24(2): 166–9PubMedCrossRef
108.
Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002 Feb 15; 73(3): 473–5PubMedCrossRef
109.
Büchler M, Hurault de Ligny B, Madec C, et al. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003 Dec; 17(6): 539–45PubMedCrossRef
110.
Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation 2000 Mar 15; 69(5): 799–805PubMedCrossRef
111.
Guttmann RD, Flemming C. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. Clin Transplant 1997 Jun; 11(3): 185–92PubMed
112.
Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005 Mar 27; 79(6): 716–21PubMedCrossRef
113.
Thibaudin D, Alamartine E, de Filippis JP, et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998 Mar; 13(3): 711–5PubMedCrossRef
114.
Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006 Aug; 19(8): 629–35PubMedCrossRef
115.
Gruber SA, West MS, Sillix DH, et al. Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients. Surgery 2005 Oct; 138(4): 772–8; discussion 8-9PubMedCrossRef
116.
Haririan A, Sillix DH, Morawski K, et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 2006 Oct; 6(10): 2396–402PubMedCrossRef
117.
Jaber JJ, Feustel PJ, Elbahloul O, et al. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007 Jan–Feb; 21(1): 101–9PubMedCrossRef
118.
Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001 Sep; 1(3): 278–83PubMedCrossRef
119.
Rajab A, Pelletier RP, Henry ML, et al. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006 Sep–Oct; 20(5): 537–46PubMedCrossRef
120.
Alexander JW, Goodman HR, Cardi M, et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006 Apr; 19(4): 295–302PubMedCrossRef
121.
Cantarovich D, Giral-Classe M, Hourmant M, et al. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol Dial Transplant 2000 Oct; 15(10): 1673–6PubMedCrossRef
122.
Shaffer D, Langone A, Nylander WA, et al. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17 Suppl. 9: 31–4PubMedCrossRef
123.
Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006 May 15; 81(9): 1285–9PubMedCrossRef
124.
Préville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001 Feb 15; 71(3): 460–8PubMedCrossRef
125.
Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008 May 27; 85(10): 1425–30PubMedCrossRef
126.
Stevens RB, Mercer D, Rigley T, et al. Single-dose induction with rabbit anti-thymocyte globulin (rATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no. 538]. American Transplant Congress; 2008 May 31–Jun 4; Toronto (ON)
127.
Gaber AO, Schnitzler M, Wiloughby L, et al. Thymoglobulin induction in living donor renal transplant recipients: report from TAILOR registry [abstract]. Am J Transplant 2006; 6 Suppl. 12: 293
128.
Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis 2010 Jan; 55(1): 141–3PubMedCrossRef
129.
Kanter J, Pallardo L, Gavela E, et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant Proc 2009 Jul–Aug; 41(6): 2156–8PubMedCrossRef
130.
Issa NC, Fishman JA. Infectious complications of anti-lymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48(6): 772–86PubMedCrossRef
131.
Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005 Oct; 56(1): 155–67PubMedCrossRef
132.
Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004 Nov; 4 Suppl. 10: 59-65
133.
Opelz G, Dohler B. Lymphomas after solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant 2004; 2(4): 222–30CrossRef
134.
Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006 May 15; 81(9): 1227–33PubMedCrossRef
135.
Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007 Nov; 7(11): 2619–25PubMedCrossRef
136.
Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003 Nov 15; 76(9): 1289–93PubMedCrossRef
137.
Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005 Oct; 9(5): 622–6PubMedCrossRef
138.
Caillard S, Dharnidharka V, Agodoa L, et al. Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005 Nov 15; 80(9): 1233–43PubMedCrossRef
139.
Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005 Jul 27; 80(2): 193–7PubMedCrossRef
140.
Coleen Hastings M, Wyatt RJ, Lau KK, et al. Five years’ experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplantation 2006 Nov; 10(7): 805–10CrossRef
141.
Baron F, Storb R, Little MT. Hematopoietic cell transplantation: five decades of progress. Arch Med Res 2003 Nov–Dec; 34(6): 528–44PubMedCrossRef
142.
Ford CE, Hamerton JL, Barnes DW, et al. Cytological identification of radiation-chimaeras. Nature 1956 Mar 10; 177(4506): 452–4PubMedCrossRef
143.
Lorenz E, Uphoff D, Reid TR, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951 Aug; 12(1): 197–201PubMed
144.
Main JM, Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 1955 Feb; 15(4): 1023–9PubMed
145.
Nowell PC, Cole LJ, Habermeyer JG, et al. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res 1956 Mar; 16(3): 258–61PubMed
146.
Trentin JJ. Mortality and skin transplantability in x-irradiated mice receiving isologous, homologous or heterologous bone marrow. Proc Soc Exp Biol Med 1956 Aug–Sep; 92(4): 688–93PubMed
147.
Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer 2002 Mar; 2(3): 231–8PubMedCrossRef
148.
Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977 Apr; 49(4): 511–33PubMed
149.
Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994 Aug 1; 84(3): 941–9PubMed
150.
Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983 Dec 1; 309(22): 1347–53PubMedCrossRef
151.
Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007 Jan; 2(1): 75–91PubMedCrossRef
152.
Barnes DW, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with X rays and homologous bone marrow: preliminary communication. BMJ 1956 Sep 15; 2(4993): 626–7PubMedCrossRef
153.
Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989 May 1; 73(6): 1720–8PubMed
154.
Barrett AJ. Understanding and harnessing the graft-versusleukaemia effect. Br J Haematol 2008 Sep; 142(6): 877–88PubMedCrossRef
155.
Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997 Jun 15; 89(12): 4531–6PubMed
156.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998 Feb 1; 91(3): 756–63PubMed
157.
158.
Gratwohl A, Baldomero H, Frauendorfer K, et al. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008 Apr; 41(8): 687–705PubMedCrossRef
159.
Koh LP, Chao N. Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008 Aug; 42 Suppl. 1: S60–3PubMedCrossRef
160.
Sierra J, Martino R, Sánchez B, et al. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant 2008 Mar; 41(5): 425–37PubMedCrossRef
161.
Bray RA, Hurley CK, Kamani NR, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 2008 Sep; 14 Suppl. 9: 45–53PubMedCrossRef
162.
163.
Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev 2008 Feb; 19(1): 53–63PubMedCrossRef
164.
Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005 Feb; 35(3): 225–31PubMedCrossRef
165.
Koca E, Champlin RE. Peripheral blood progenitor cell or bone marrow transplantation: controversy remains. Curr Opin Oncol 2008 Mar; 20(2): 220–6PubMedCrossRef
166.
Remberger M, Svahn BM, Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999 Oct; 24(8): 823–30PubMedCrossRef
167.
McCaul KG, Nevill TJ, Barnett MJ, et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000 Jun; 9(3): 367–74PubMedCrossRef
168.
Chakrabarti S, Buyck HC. Reduced-intensity transplantation in the treatment of haematological malignancies: current status and future-prospects. Curr Stem Cell Res Ther 2007 May; 2(2): 163–88PubMedCrossRef
169.
Kato K, Khaled Y, Mineishi S. Reduced-intensity stem cell transplantation for hematological malignancies: current status and the future. Curr Stem Cell Res Ther 2007 May; 2(2): 149–62PubMedCrossRef
170.
Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001 Nov 15; 98(10): 2942–7PubMedCrossRef
171.
Duggan P, Booth K, Chaudhry A, et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002 Nov; 30(10): 681–6PubMedCrossRef
172.
Bacigalupo A, Lamparelli T, Gualandi F, et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002; 8(12): 656–61PubMedCrossRef
173.
Remberger M, Storer B, Ringdén O, et al. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002 Mar; 29(5): 391–7PubMedCrossRef
174.
Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005 May; 35(10): 1011–8PubMedCrossRef
175.
Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8(9): 468–76PubMedCrossRef
176.
Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007 Jul; 13(7): 814–21PubMedCrossRef
177.
Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006 May; 12(5): 573–84PubMedCrossRef
178.
Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant anti-thymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007 Mar; 13(3): 299–306PubMedCrossRef
179.
Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008 Jun; 14(6): 672–84PubMedCrossRef
180.
Russell JA, Duan Q, Chaudhry MA, et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008 Aug; 14(8): 888–95PubMedCrossRef
181.
Russell J, Irish W, Savoie L, et al. Regimen intensity in acute myelogenous leukemia: addition of 400 cGy total body irradiation to a myeloablative fludarabine/busulphan/thymoglobulin allogeneic transplant regimen reduces relapse without increasing transplant-related mortality [abstract no. O400]. Bone Marrow Transplant 2008; 41: S74
182.
Carella AM. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine. Hematol J 2004; 5 Suppl. 1: S68–75PubMedCrossRef
183.
Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003 Jul 15; 102(2): 470–6PubMedCrossRef
184.
Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003 Nov; 17(11): 2168–77PubMedCrossRef
185.
Mohty M, Mohty AM, Blaise D, et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004 Apr; 33(8): 839–46PubMedCrossRef
186.
Lowsky R. Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. Transplantation 2007 Dec 15; 84(11S): S20–6CrossRef
187.
Maki T, Simpson M, Monaco AP. Development of suppressor T cells by antilymphocyte serum treatment in mice. Transplantation 1982 Dec; 34(6): 376–81PubMedCrossRef
188.
Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005 Sep 29; 353(13): 1321–31PubMedCrossRef
189.
Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol 2006 Oct; 17(10): 2844–53PubMedCrossRef
190.
Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+ CD25highFOXP3+ regulatory T cells in vitro. Blood 2008 Apr 1; 111(7): 3675–83PubMedCrossRef
191.
Lan F, Zeng D, Higuchi M, et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003 Jun; 9(6): 355–63PubMedCrossRef
192.
Lan F, Zeng D, Higuchi M, et al. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: “natural suppressor” cells. J Immunol 2001 Aug 15; 167(4): 2087–96PubMed
193.
Meijer E, Cornelissen JJ, Löwenberg B, et al. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 2003 Nov; 31(11): 1026–30PubMedCrossRef
194.
Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004 Jul 15; 78(1): 122–7PubMed
195.
Dominietto A, Van Lint MT, Gaulandi F, et al. Is timing of anti-thymocyte globulin (ATG) — pre and post hematopoietic stem cell transplants (HSCT) — relevant for graft vs host disease (GVHD)? [abstract no. 851]. Blood 2003; 102: 242a
196.
197.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006 Oct 15; 108(8): 2509–19PubMedCrossRef
198.
Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 2000 Jan; 37(1): 56–68PubMedCrossRef
199.
Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant 2008 Aug; 42 Suppl. 1: S42–S4PubMedCrossRef
200.
Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006 Jun; 133(6): 622–7PubMedCrossRef
201.
Fang JP, Xu HG, Huang SL, et al. Immunosuppressive treatment of aplastic anemia in Chinese children with antithymocyte globulin and cyclosporine. Pediatr Hematol Oncol 2006 Jan–Feb; 23(1): 45–50PubMedCrossRef
202.
Garg R, Faderl S, Garcia-Manero G, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 2009 Feb 26; 23(7): 1297–302PubMedCrossRef
203.
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 Dec 20; 357(25): 2601–14PubMedCrossRef
204.
Brayman K. New insights into the mechanism of action of thymoglobulin. Transplantation 2007 Dec 15; 84(11S): S3–4CrossRef
205.
Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57: 381–402PubMedCrossRef
206.
Sánchez-Fueyo A, Sandner S, Habicht A, et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol 2006 Jan 1; 176(1): 329–34PubMed
207.
Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002 Aug 5; 196(3): 389–99PubMedCrossRef
208.
Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003 May 3; 361(9368): 1502–10PubMedCrossRef
209.
D’Addio F, Yuan X, Williams J, et al. Low dose prolonged mATG therapy: a novel clinically relevant approach to promote regulation and induce long-term allograft survival [abstract no. F-FC241]. Renal Week 2008: 41st Annual Meeting and Scientific Exposition, American Society of Nephrology; 2008 Nov 4–9; Philadelphia (PA)
210.
Sykes M. Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation 2009 Feb 15; 87(3): 309–16PubMedCrossRef
211.
Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008 Jan 24; 358(4): 353–61PubMedCrossRef
212.
Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008 Jan 24; 358(4): 362–8PubMedCrossRef
213.
214.
Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005 Feb 16; 293(7): 830–5PubMedCrossRef
215.
Meloche RM. Transplantation for the treatment of type 1 diabetes. World J Gastroenterol 2007 Dec 21; 13(47): 6347–55PubMedCrossRef
216.
Monaco AP, Morris PJ. Editorial comment: a role for alloimmune response mediators in tolerance induction? Transplantation 2007; 84 Suppl. 1: S1–2PubMedCrossRef
217.
Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007 Apr 11; 297(14): 1568–76PubMedCrossRef
218.
219.
Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit anti-thymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005 Jun 15; 79(11): 1507–15PubMedCrossRef
220.
Ruzek M, Dzuris J, Gao L, et al. Selected mechanistic studies and future directions for Thymoglobulin. Transplantation 2007 Dec 15; 84(11S): S27–34CrossRef
221.
Zand MS. Therapeutic antibody agents for B-cell immunomodulation in renal transplantation. Transplantation 2007; 84(11S): S11–9CrossRef
222.
Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006 Dec 15; 82(11): 1387–95PubMedCrossRef
223.
Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 Dec; 54(12): 3750–60PubMedCrossRef
224.
Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992 Jun; 6(3): 607–18PubMed
225.
Kondo Y, Molldrem JJ. Immune-induced cytopenia: bone marrow failure syndrome. Curr Hematol Rep 2004 May; 3(3): 178–83PubMed
226.
Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008 May 20; 26(15): 2505–11PubMedCrossRef
227.
Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immunemodulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004 Mar; 18(3): 460–5PubMedCrossRef
Metadata
Title
Rabbit Antithymocyte Globulin (Thymoglobulin®)
25 Years and New Frontiers in Solid Organ Transplantation and Haematology
Authors
Dr A. Osama Gaber
Anthony P. Monaco
James A. Russell
Yvon Lebranchu
Mohamad Mohty
Publication date
01-04-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11315940-000000000-00000

Other articles of this Issue 6/2010

Drugs 6/2010 Go to the issue

Adis Drug Evaluation

Strontium Ranelate

Adis Drug Evaluation

Levobupivacaine

Review Article

Ethinylestradiol/Dienogest in Oral Contraception

Current Opinion

Combination Pharmacotherapy for Stopping Smoking

Leading Article

Current Challenges in Antimicrobial Chemotherapy